AUTHORS
Alexia Kessler, Ahmad Al-Huniti, MD2, Mira A. Kohorst, MD3, Chung II Wi, MD4, Kimberly Langer, CNP5, Markie Zimmer, MD6, Mrinal M. Patnaik, MD, MBBS7, Alejandro Ferrer, PhD8, Ajoy Lawrence Dias, MD9, Tariq Kewan, MD10, Hassan B Alkhateeb, M.D.11, Mithun Shah, MD, PhD12, Aasiya Matin, MBBS13, Mehrdad Hefazi Torghabeh, MD14, William Hogan, M.B., B.Ch.15, Abhishek Avinash Mangaonkar, MBBS16, Anand Srinivasan, MBBS17
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background:
Socioeconomic status (SES) has been shown to influence outcomes after allogeneic hematopoietic stem cell transplantation (HSCT), but prior studies have primarily relied upon neighborhood-level proxies that do not necessarily reflect individual socioeconomic circumstances. Data on the impact of SES on HSCT outcomes in patients with bone marrow failure (BMF) is limited. We evaluated whether the HOUsing-based SocioEconomic Status (HOUSES) index, a validated individual-level SES measure, was associated with outcomes after allogeneic HSCT for BMF.
Methods:
We performed a retrospective cohort study of pediatric and adult patients undergoing allogeneic HSCT for acquired or inherited BMF at Mayo Clinic between 2009 and 2025. Primary endpoint was overall survival. Secondary endpoints included primary and secondary graft failure, infections, acute and chronic graft-versus-host disease (GVHD), and engraftment. Individual-level SES was measured using the HOUSES index.
The Housing-Based Socioeconomic Status (HOUSES) index was developed, validated, and implemented by Mayo Clinic using a novel index for measuring individual socioeconomic status based on housing features. The HOUSES Program enables large-scale, objective measurements of patient-level social determinants of health. The program applies principal component factor analysis based on real property data features of housing and neighborhood socioeconomic status items. Factor analysis results are then pared down to four real property feature variables (a) housing value, (b) square footage of housing unit, (c) number of bedrooms and (d) number of bathrooms. In formulating the HOUSES Index, the patient's address at the time of query is geocoded. Geocoding allows matching the study addresses to geographic reference data and real property data of a housing unit. Each property item corresponding to a person's address is standardized into a z-score and aggregated into an overall z-score for the four variables mentioned above, such that a higher HOUSES score indicates higher socioeconomic status.
The Area Deprivation Index (ADI) is another scientifically validated measure of the neighborhood's disadvantage and is used to evaluate and improve factors that impact health across populations.
Univariable logistic regression evaluated associations between SES measures and secondary endpoints. Kaplan-Meier analysis compared survival between adult and pediatric transplant programs.
Results:
Fifty-three patients underwent allogeneic HSCT (35 adults, 18 pediatric). Median follow-up was 6.9 years, during which eight deaths occurred. Median HOUSES percentile was similar among patients with versus without any infection, IV antibiotic/sepsis infection, any acute GVHD, grade II–IV acute GVHD, any graft failure, and composite endpoints. In univariable logistic regression scaled per 10-point increase in HOUSES percentile, odds ratios were close to 1 for any infection, severe infection, acute GVHD, graft failure, and composite outcomes. Program-adjusted sensitivity models produced similar findings, with no statistically significant association between HOUSES percentile and any complication endpoint. HOUSES Index percentile was not significantly associated with any early complication post-transplant endpoint.
Mortality did not differ between adult and pediatric transplant programs (14.3% vs. 16.7%) and was not associated with HOUSES or other SES measures. As expected, and based on previous studies, presence of acute GVHD and age ≥21 increased risk of chronic GVHD with OR of 11 (95% CI 2-81) and 9 (95% CI 1.4-172) respectively. Higher ADI national rank seemed to be associated with increased odds of only one secondary endpoint: Secondary graft failure in the overall cohort (OR 1.10; 95% CI 1.02-1.23) and specifically in pediatric recipients (OR 1.09; 95% CI 1.01-1.27).
Conclusions:
In this exploratory single-center cohort analysis, individual-level SES measured by the HOUSES index did not appear to impact outcomes following allogeneic HSCT for BMF. Higher ADI was associated with only one adverse outcome post-transplant (secondary graft failure). However, these findings should be interpreted cautiously given the limited number of events and our small sample size. Our study also indicate that the HOUSES index and ADI both correlate well as measures of SES. Large multicenter studies are warranted to study the impact of SES on transplant outcomes in patients with BMF.
DISCLOSURES
Alexia Kessler: No relevant conflicts of interest to declare.